Medicamen Biotech Limited has informed the Exchange about Copy of Newspaper Publication
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech has shared copies of the newspaper publication of its unaudited financial results for the quarter ended June 30, 2025, which were originally approved by the Board on August 12, 2025. The results were published in Financial Express and Jansatta on August 13, 2025 as required by SEBI rules. On a standalone basis, the company posted a net loss of about ₹79.70 lakhs on near-zero revenue of ₹0.05 lakhs. On a consolidated basis, the net loss narrowed to about ₹16.10 lakhs on revenue of ₹172.89 lakhs. This filing is purely a procedural compliance confirming that the results were published in newspapers as mandated.
No new information for investors — the underlying Q1 results were already approved and disclosed earlier. The continued losses on both standalone and consolidated basis remain a concern, but this particular filing is a routine regulatory step and is unlikely to move the stock on its own.